Cargando…
Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?
A key objective in immuno-oncology is to reactivate the dormant immune system and increase tumour immunogenicity. Adenosine is an omnipresent purine that is formed in response to stress stimuli in order to restore physiological balance, mainly via anti-inflammatory, tissue-protective, and anti-nocic...
Autores principales: | Kotulová, Jana, Hajdúch, Marián, Džubák, Petr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617980/ https://www.ncbi.nlm.nih.gov/pubmed/34830449 http://dx.doi.org/10.3390/ijms222212569 |
Ejemplares similares
-
2-Cl-IB-MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines
por: Kotulova, Jana, et al.
Publicado: (2022) -
Ayushman Bharat Initiative (2018): What we Stand to Gain or Lose!
por: Bakshi, Harsh, et al.
Publicado: (2018) -
Adenosinergic System and Neuroendocrine Syncope: What Is the Link?
por: Guieu, Régis, et al.
Publicado: (2023) -
Differential Regulation of Methylation-Regulating Enzymes by Senescent Stromal Cells Drives Colorectal Cancer Cell Response to DNA-Demethylating Epi-Drugs
por: Agrawal, Khushboo, et al.
Publicado: (2018) -
Impact on the individual: what do patients and carers gain, lose and expect from being involved in research?
por: Ashcroft, Joanne, et al.
Publicado: (2016)